We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
- Authors
Marcelin, A. G.; Charpentier, C.; Wirden, M.; Landman, R.; Valantin, M. A.; Simon, A.; Katlama, C.; Yeni, P.; Descamps, D.; Aubron-Olivier, C.; Calvez, V.
- Abstract
Objectives To compare the frequency of the selection of the M184V/I resistance mutation in HIV-infected patients who experienced virological failure while receiving emtricitabine (FTC) or lamivudine (3TC), administered with tenofovir disoproxil fumarate (TDF) and either efavirenz (EFV) or a ritonavir-boosted protease inhibitor (PI; lopinavir or atazanavir). Methods Patient data held at two clinical centres in France were analysed retrospectively. Eligible patients had experienced virological suppression (plasma HIV RNA <200 copies/mL) for ≥6 months before experiencing their first virological failure (at least two measurements of plasma HIV RNA ≥200 copies/mL). Results Of the 880 patients eligible for the study, 278 patients had experienced virological failure while receiving FTC + TDF + ritonavir-boosted PI, 257 while receiving FTC + TDF + EFV, 178 while receiving 3TC + TDF + EFV and 167 while receiving 3TC + TDF + ritonavir-boosted PI. Proportions of patients harbouring the M184V/I mutation were 24% (n = 62) for those who received FTC + TDF + EFV versus 51% (n = 91) for 3TC + TDF + EFV (P < 0.0001; Fisher’s exact test); proportions were 11% (n = 30) for FTC + TDF + ritonavir-boosted PI versus 22% (n = 37) for 3TC + TDF + ritonavir-boosted PI (P = 0.002; Fisher’s exact test). The use of lamivudine versus emtricitabine (P = 0.001), non-nucleoside reverse transcriptase inhibitors versus ritonavir-boosted PIs (P = 0.01) and the level of viral load at the time of virological failure (P = 0.01) were associated with selection of the M184V/I mutation (logistic regression analysis). Conclusions Emtricitabine and lamivudine showed differing resistance profiles when administered in combination with tenofovir disproxil fumarate and either efavirenz or a ritonavir-boosted PI. The prevalence of the M184V/I resistance mutation was significantly lower in patients who received emtricitabine and tenofovir disoproxil fumarate than in those who received lamivudine and tenofovir disoproxil fumarate.
- Subjects
HIV-positive persons; VIROLOGY; EMTRICITABINE; LAMIVUDINE; TENOFOVIR
- Publication
Journal of Antimicrobial Chemotherapy (JAC), 2012, Vol 67, Issue 6, p1475
- ISSN
0305-7453
- Publication type
Article
- DOI
10.1093/jac/dks047